Tag: paclitaxel

ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices

Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky,...

Innovation: ISET audience hears what’s on the horizon for CLTI patients

“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider, MD, professor of vascular and endovascular surgery...

FDA representatives respond to SWEDEPAD interim analysis, highlight need for continued...

Representatives from the Food and Drug Administration (FDA) referenced "important and reassuring" results from the recent interim analysis of the SWEDEPAD clinical trial in which...

SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for...

An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease (PAD) received treatment with paclitaxel-coated (drug-coated balloons...

New analysis finds DCBs lead to greater four-year survival after fempop...

Patients treated with a paclitaxel-coated balloon saw greater survival, freedom from amputation and amputation-free survival through four-year follow-up after their initial femoropopliteal revascularization operation...

TCT 2020 late-breaking trials session features new data on drug-coated devices

Findings from a series of late-breaking trials in the endovascular field were delivered recently at TCT Connect (Oct. 14–18), the 32nd annual scientific symposium...

Vascular surgeons encouraged to consult talking points document on paclitaxel devices

Vascular surgeons are being encouraged to take consideration of a set of talking points about the risks and benefits of paclitaxel-equipped devices—which has been...

IN.PACT Admiral DCB shows ‘significant advantage’ over uncoated devices in fempop...

The IN.PACT Admiral drug-coated balloon (DCB) demonstrated a significant advantage in overall survival, amputation-free survival and target-lesion revascularization after femoropopliteal artery treatment through four-year...

September slate of regional vascular meetings goes digital

This time last year, the ranks of vascular surgery were gearing up to head for points East, West, Midwest and Northeast as the slew...

High level of heterogeneity found in randomized PAD trial antithrombotic regimens

A recent systematic review showed that randomized trials comparing different types of peripheral endovascular arterial intervention have a high level of heterogeneity in their...

Six-month IN.PACT AV Access results show superiority of DCB angioplasty

Just-published six-month results of the IN.PACT AV Access study show that drug-coated balloon (DCB) angioplasty is superior to standard angioplasty for the treatment of...

MHRA: Warning to be added to paclitaxel device IFUs in Europe

In a new field safety notice, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) states that a warning and clinical summary section will be...

CX 2020 LIVE pioneers virtual vascular conference format in COVID-19 era

CX 2020 LIVE came to life online—despite COVID-19—using state-of-the art broadcast technology to bring together more than 1,000 vascular specialists, live, from 95 countries across...

FDA official delivers government agency’s early reaction to latest contentious meta-analysis...

HOLLYWOOD, Fla.—A Food and Drug Administration (FDA) official delivered a talk which represents the government agency’s earliest public reaction to the latest meta-analysis suggesting...
x-ray image below knee amputation or BKA amputation

Deploying robust, detailed SVS VQI data to help better define role...

In December 2018, the Journal of the American Heart Association published “Risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal...

New meta-analysis finds ‘no observed difference’ in mortality between paclitaxel and...

February 2020 brings another paclitaxel device meta-analysis of randomized controlled trials in chronic limb-threatening ischemia (CLTI) patients. Krystal Dinh, BMed, of Westmead Hospital, Sydney,...

SVS president presents point-by-point defense of Society position on paclitaxel controversy

NEW YORK—Kim Hodgson, MD, president of the Society for Vascular Surgery, delivered a robust defense of the SVS position on the drug-coated balloon (DCB)...
x-ray image below knee amputation or BKA amputation

Hotly-contested meta-analysis suggests a higher risk of death or amputation at...

A new meta-analysis, just published in the Journal of Vascular and Interventional Radiology (JVIR), suggests significantly reduced amputation-free survival at one year when paclitaxel-coated...